ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has ...
Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback